Land: Irland
Sprog: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
Iodine; Meglumine ioxaglate; Sodium ioxaglate
Guerbet
V08AB; V08AB11
Iodine; Meglumine ioxaglate; Sodium ioxaglate
320 milligram(s)/millilitre
Solution for injection
Product subject to Restricted Prescription (C)
Watersoluble, nephrotropic, low osmolar X-ray contrast media; iobitridol
Marketed
1996-05-09
_ _ 1 HEXABRIX 320 (320 MG I/ML), SOLUTION FOR INJECTION MEGLUMINE IOXAGLATE AND SODIUM IOXAGLATE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What HEXABRIX 320, solution for injection is and what it is used for 2. What you need to know before you use HEXABRIX 320, solution for injection 3. How to use HEXABRIX 320, solution for injection 4. Possible side effects 5. How to store HEXABRIX 320, solution for injection 6. Contents of the pack and other information 1. WHAT HEXABRIX 320 IS AND WHAT IT IS USED FOR HEXABRIX 320 is a contrast agent. It belongs to the group of contrast agents used for radiological examinations. HEXABRIX 320 is used to enhance the contrast of the images obtained during these examinations, in order to improve the visualisation and delineation of certain parts of the body, such as: Certain hollow organs (opacification of body cavities), The uterus and fallopian tubes (ducts connecting the uterus to the ovaries) in female patients (hysterosalpingography), Blood vessels (angiography), Joints (arthrography), Urinary system (urography). This medicine is for diagnostic use only. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE HEXABRIX 320 YOUR DOCTOR MUST NEVER GIVE YOU HEXABRIX 320 IN THE FOLLOWING CASES: If you are allergic to the active substance (ioxaglic acid) or any of the other ingredients of HEXABRIX 320. The list of these ingredients can be found in section 6. Contents of the pack and other information. If you have already had an allergic reaction following the injection of a medicinal product containing the same active Læs hele dokumentet
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Hexabrix 320 Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Ioxaglic acid 53.33 % w/v equivalent to 320 mg iodine per millilitre of solution. Ioxaglic acid is present as meglumine ioxaglate and sodium ioxaglate. (Sodium content:153 mEq/1) For full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection Clear, colourless to pale yellow solution with a pH of 6.5 to 7.6 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Low osmolar X-ray contrast medium for the opacification of the vascular system, urinary tract and joints and hysterosalpingography. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Procedure Product Dosage and Administration Femoral and other peripheral arteriographies Hexabrix 320 15-20 ml. A similar or smaller dose is indicated for smaller arteries Cerebral angiography (carotid and vertebral) Hexabrix 320 Average adult dose: 6 - 8 ml for each injection. Up to 10 injections may be required. Angiocardiography Hexabrix 320 Multiple small test injections may be used for positioning catheter tip. _Adults_: 30-50 ml per injection Children and infants: 1-1, 5 ml per kg body weight. Multiple injections may be required, although total dosage should not normally exceed 4 ml per kg body weight. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _1_ _0_ _/_ _0_ _4_ _/_ _2_ _0_ _1_ _7_ _C_ _R_ _N_ _ _ _2_ _1_ _9_ _1_ _2_ _7_ _3_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ Læs hele dokumentet